The rapid response to the COVID-19 pandemic and fast delivery of safe and effective vaccines and antiviral therapies were a clear demonstration of the biopharmaceutical industry’s ability to innovate. That effort inspired the theme for this year’s BIO International Convention, the first to be held in person since 2019 because of the pandemic, of being “Limitless Together.”
BIO 2022: ‘Limitless’ Innovation Is Harder With Limited Cash
The mid-year meeting offered a chance to reflect on the tumultuous times and look at how the biopharma industry can weather the storm.
More from Strategy
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
• By
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
More from Business
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
• By
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.
• By
MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.